Overview

Maximal Use Systemic Exposure (MUSE) Study of Levulan Kerastick

Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the potential for systemic exposure of aminolevulinic acid (ALA) when applied topically under occlusion, in a maximal use setting in patients with multiple actinic keratoses (AK) involving the upper extremities.
Phase:
Phase 2
Details
Lead Sponsor:
DUSA Pharmaceuticals, Inc.
Treatments:
Aminolevulinic Acid